Page last updated: 2024-08-17

quinidine and cilostazol

quinidine has been researched along with cilostazol in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bramer, SL; Suri, A1
Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B1
Aizawa, Y; Ashihara, T; Hasegawa, K; Horie, M; Itoh, H; Jo, H; Kimura, H; Yamamoto, T1

Reviews

1 review(s) available for quinidine and cilostazol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for quinidine and cilostazol

ArticleYear
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Clinical pharmacokinetics, 1999, Volume: 37 Suppl 2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Area Under Curve; Cilostazol; Cross-Over Studies; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Metoprolol; Middle Aged; Quinidine; Tetrazoles; Vasodilator Agents

1999

Other Studies

5 other study(ies) available for quinidine and cilostazol

ArticleYear
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
MICE models: superior to the HERG model in predicting Torsade de Pointes.
    Scientific reports, 2013, Volume: 3

    Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
    Circulation. Arrhythmia and electrophysiology, 2014, Volume: 7, Issue:1

    Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electrocardiography; Heart Conduction System; Hypothermia, Induced; Milrinone; Perfusion; Phosphodiesterase 3 Inhibitors; Quinidine; Signal Transduction; Tachycardia, Ventricular; Tetrazoles; Time Factors; Ventricular Fibrillation

2014
Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:14

    Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Heart Conduction System; Humans; Male; Middle Aged; Phosphodiesterase 3 Inhibitors; Quinidine; Tetrazoles; Time Factors

2014